section name header

Pronunciation

ole-SAL-a-zeen

Classifications

Therapeutic Classification: gastrointestinal anti-inflammatories

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Acts locally in colon, where 98–99% is converted to mesalamine (5-aminosalicylic acid).

Distribution: Action is primarily local and remains in the colon.

Metabolism/Excretion: 2% absorbed into systemic circulation is rapidly metabolized; mostly eliminated as mesalamine in the feces.

Half-life: 0.9 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown1 hr; 4–8 hr12 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS (AGEP), DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), itching, photosensitivity, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN).

GI: diarrhea, abdominal pain, anorexia, exacerbation of colitis, HEPATOTOXICITY, nausea, vomiting.

GU: interstitial nephritis, nephrolithiasis, renal impairment.

Hemat: blood dyscrasias.

Neuro: ataxia, confusion, depression, dizziness, drowsiness, headache, psychosis, restlessness.
Misc: acute intolerance syndrome, hypersensitivity reactions.

Interactions

Drug-Drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Dipentum